Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has announced encouraging results of preclinical animal studies focused on multiple myeloma that were conducted concurrently at Mayo Clinic and the University of Waterloo.
Subscribe to our email newsletter
The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco’s Factor 5A technology to induce apoptosis in tumors. Additionally, the studies evaluated the efficacy of nanoparticles as a vehicle for encapsulation and delivery of Factor 5A to tumors. SCID (severe combined immunodeficiency) mice were injected subcutaneously with human multiple myeloma cancer cells to form myeloma tumors in their flanks. Treated mice were injected intratumorally with Factor 5A therapy encapsulated in nanoparticles, while control mice received a nanoparticle without the Factor 5A therapy. One of the dosing regimens showed evidence of significant tumor regression relative to the untreated control mice, while the other showed a diminished rate of tumor growth along with some regression.
The company believes that the results of this study, together with the results of previous studies may be sufficient to plan the preclinical toxicology studies to support an investigational new drug application at the FDA.